BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera

Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to buy right now. On December 16, Bank of America analyst Jason Gerberry lowered the firm’s price target on Pfizer to $27 from $28 while keeping a Neutral rating on the shares. Pfizer’s 2026 guidance revealed a steeper erosion of its COVID-19 franchise than previously projected, leading the firm to trim its near-term financial forecasts. The focus has now shifted to the company’s obesity strategy; investors are awaiting trial results from the recently acquired Metsera assets to determine if they can successfully carve out a unique position in the high-growth weight-loss market.

Additionally, on December 17, Pfizer and Astellas announced positive topline results from the Phase 3 EV-304 trial (KEYNOTE-B15). The study showed that the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) significantly improved both event-free survival and overall survival when used as a perioperative treatment (before and after surgery) for patients with muscle-invasive bladder cancer/MIBC. This trial specifically focused on patients eligible for cisplatin-based chemotherapy, the current standard of care.

The trial also met its secondary endpoint of pathologic complete response rate, showing a statistically significant improvement over traditional neoadjuvant chemotherapy. These findings, combined with earlier results from the EV-303 trial, position the PADCEV and Keytruda combination as a potential platinum-free standard of care for MIBC patients, regardless of their eligibility for cisplatin. Currently, bladder cancer is diagnosed in over 614,000 patients globally each year, with MIBC accounting for ~30% of those cases.

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.